Cardio-Oncology: Bridging the Gap Between Cardiovascular Health and Cancer Care
- Authors
-
-
Hadi N Skouri
Division of Cardiology, Sheikh Shakbout Medical City-Mayo Clinic, Abu Dhabi, United Arab Emirates
-
- Keywords:
- Cardio-oncology, Cardiotoxicity, Chemotherapy-Cardiotoxicity, Radiotherapy-Cardiotoxicity, Biomarkers
- Abstract
-
Cardio-oncology, an emerging subspecialty, is the study of the intersection of cardiovascular disease (CVD) and cancer. This field focuses on the prevention, diagnosis, and management of cardiovascular complications arising from cancer therapies. Given the increasing prevalence of cardiotoxicity induced by chemotherapy, targeted therapy, immunotherapy, and radiotherapy, this field plays a critical role in improving patient outcomes. Cardiotoxicity is characterized by a range of physiological manifestations, including cardiac dysfunction or heart failure, hypertension, arrhythmias, venous and arterial thromboembolism, pericardial disease, and pulmonary hypertension. Furthermore, the administration of certain pharmaceutical agents has been demonstrated to induce metabolic disturbances, which can manifest as an increased propensity for the development of diabetes or dyslipidemia, or the exacerbation of preexisting conditions. Chemotherapy-related cardiac dysfunction (CTRCD) manifests in two primary forms: type I, characterized by irreversible myocardial cell damage (e.g., anthracycline-induced cardiotoxicity), and type II, involving reversible myocardial dysfunction (e.g., trastuzumab-induced cardiotoxicity). Biomarkers, such as cardiac troponin (cTn) and natriuretic peptides (NP), play a pivotal role in the early detection of heart failure. Advanced imaging techniques, including cardiac MRI and speckle-tracking echocardiography, have been shown to enhance monitoring capabilities. Radiotherapy has been shown to have deleterious effects on cardiovascular health, contributing to the development of conditions such as coronary artery disease, valvular dysfunction, pericardial disease, and myocardial fibrosis. This review underscores the importance of multidisciplinary collaboration, early screening, and monitoring through innovative diagnostic tools to mitigate cardiovascular risks in cancer patients, ultimately enhancing survivorship and quality of life.
- References
-
Abdul-Rahman, T., Dunham, A., Huang, H., Bukhari, S. M. A., Mehta, A., Awuah, W. A., Ede-Imafidon, D., Cantu-Herrera, E., Talukder, S., Joshi, A., Sundlof, D. W., & Gupta, R. (2023). Chemotherapy Induced Cardiotoxicity: A State of the Art Review on General Mechanisms, Prevention, Treatment and Recent Advances in Novel Therapeutics. Current Problems in Cardiology, 48(4), 101591. https://doi.org/10.1016/j.cpcardiol.2023.101591
Ganatra, S., Chatur, S., & Nohria, A. (2020). How to Diagnose and Manage Radiation Cardiotoxicity. JACC: CardioOncology, 2(4), 655–660. https://doi.org/10.1016/j.jaccao.2020.07.010
Hayek, S. S., Ganatra, S., Lenneman, C., Scherrer-Crosbie, M., Leja, M., Lenihan, D. J., Yang, E., Ryan, T. D., Liu, J., Carver, J., Mousavi, N., O’Quinn, R., Arnold, A., Banchs, J., Barac, A., & Ky, B. (2019). Preparing the Cardiovascular Workforce to Care for Oncology Patients. Journal of the American College of Cardiology, 73(17), 2226–2235. https://doi.org/10.1016/j.jacc.2019.02.041
Huang, W., Xu, R., Zhou, B., Lin, C., Guo, Y., Xu, H., & Guo, X. (2022). Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Frontiers in Cardiovascular Medicine, 9. https://doi.org/10.3389/fcvm.2022.912329
Koutsoukis, A., Ntalianis, A., Repasos, E., Kastritis, E., Dimopoulos, M.-A., & Paraskevaidis, I. (2018). Cardio-oncology: A Focus on Cardiotoxicity. European Cardiology Review, 13(1), 64. https://doi.org/10.15420/ecr.2017:17:2
Li, G., Zhang, L., & Liu, M. (2023). Evolving field of cardio-oncology. Cancer Pathogenesis and Therapy, 1(2), 141–145. https://doi.org/10.1016/j.cpt.2023.02.002
Narowska, G., Gandhi, S., Tzeng, A., & Hamad, E. A. (2023). Cardiovascular Toxicities of Radiation Therapy and Recommended Screening and Surveillance. Journal of Cardiovascular Development and Disease, 10(11), 447. https://doi.org/10.3390/jcdd10110447
Pizzino, F., Vizzari, G., Bomzer, C. A., Qamar, R., Carerj, S., Zito, C., & Khandheria, B. K. (2014). Diagnosis of Chemotherapy-Induced Cardiotoxicity. Journal of Patient-Centered Research and Reviews, 1(3), 121–127. https://doi.org/10.17294/2330-0698.1025
Tetterton-Kellner, J., Jensen, B. C., & Nguyen, J. (2024). Navigating cancer therapy induced cardiotoxicity: From pathophysiology to treatment innovations. Advanced Drug Delivery Reviews, 211, 115361. https://doi.org/10.1016/j.addr.2024.115361
- Published
- 2025-05-28
- Section
- Letters/Short Reports/Communications
- Categories
- License
-
Copyright (c) 2025 Hadi N Skouri

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
Similar Articles
- Ali Sedeeq, Shaiban Abdulsalam Almukhtar, Azzam Ahmed Abduljabbar, Knowledge of Ovarian Cancer Risk Factors and Symptoms Among Iraqi Women in Baghdad: A Cross-Sectional Study , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 2 (2025): April - June
- Sami S. Omar, Basak Barzngy, Sawen Dizay, Tamara A. Almufty, Fairuz A. Kakasur, Savan Saeed, Multiple Hepatic Epithelioid Hemangioendothelioma; A Rare Case Report , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 2 (2025): April - June
- Dr. Abdul Rasool Hassan , Assessing Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients in Malaysia: Insights into Quality of Life and Genetic Influences , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 1 (2025): January - March
- Suha Ali Hammed, Alaa Fadhil Alwan, Metastatic EGFR-Mutant Lung Adenocarcinoma Patients: A Safety and Efficacy Analysis of First- and Third-Generation EGFR-TKIs , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 4 (2025): October - December
- Reem Mohammed Jawad, Adil S Aqabi, Zeineb Adnan, The Impact of Obesity on Survival in Iraqi Patients with Epithelial Ovarian Cancer , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 4 (2025): October - December
- Badiaa Batlamous, Boutaina Elgharbaoui, Imane Bensalim, Mohamed Khalis, Mechanisms of Chemoresistance in Solid and Hematologic Malignancies: Challenges and Future Perspectives , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 3 (2025): July - September
- Ali Haider Mohammed, Lim Jie Sern, Lim Jing Xuan, Leong Jia Yun, Lim Jing En, Medicinal Plants Commonly Used Against Cancer and Human Immunodeficiency Virus in Malaysia , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 1 (2025): January - March
- Zainab Mohamed Alaa Alhelli, Amaal Mohammed Alhelli, Aadil S Aqabi, Body Mass Index and Risk of Post‑Treatment Relapse in Endometrial Cancer: Evidence from an Iraqi Cross‑Sectional Cohort , Middle Eastern Cancer and Oncology Journal: Vol. 1 No. 4 (2025): October - December
You may also start an advanced similarity search for this article.
